CORRESP

0001193125-18-143255.txt : 20180604 0001193125-18-143255.hdr.sgml : 20180604 20180430162602 ACCESSION NUMBER: 0001193125-18-143255 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20180430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASLAN Pharmaceuticals Ltd CENTRAL INDEX KEY: 0001722926 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 83 CLEMENCEAU AVENUE STREET 2: #12-03 UE SQUARE CITY: SINGAPORE STATE: U0 ZIP: 239920 BUSINESS PHONE: 65 6222 4235 MAIL ADDRESS: STREET 1: 83 CLEMENCEAU AVENUE STREET 2: #12-03 UE SQUARE CITY: SINGAPORE STATE: U0 ZIP: 239920 CORRESP 1 filename1.htm CORRESP

LOGO

83 Clemenceau Avenue #12-03 UE Square

Singapore 239920

VIA EDGAR

April 30, 2018

U.S. Securities and Exchange Commission

Office of Healthcare and Insurance

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn:

Ms. Irene Paik

Mr. Christopher Edwards

Re:

ASLAN Pharmaceuticals Limited

Registration Statement on Form F-1

File No. 333-223920


Acceleration Request
Requested Date:		Wednesday, May 2, 2018
Requested Time:		4:00 P.M. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-1 to become effective on May 2, 2018, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as its counsel may orally request via telephone call to the staff. The Registrant hereby authorizes each of Robert Phillips and Charles Kim of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Robert Phillips of Cooley LLP at (415) 693-2020, or in his absence, Charles Kim at (858) 550-6049. Thank you for your assistance with this matter.


Sincerely,

ASLAN Pharmaceuticals Limited

By:		/s/ Carl Firth
		Carl Firth, Ph.D.
		Chief Executive Officer and Chairman


cc:		Kiran Asarpota, ASLAN Pharmaceuticals Limited
		Robert W. Phillips, Cooley LLP
		Sean M. Clayton, Cooley LLP
		Charles S. Kim, Cooley LLP
		Patrick Loofbourrow, Cooley LLP
		Alan F. Denenberg, Davis Polk & Wardwell LLP

GRAPHIC 2 g496922g97i29.jpg GRAPHIC begin 644 g496922g97i29.jpg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end